期刊
MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA
卷 16, 期 4, 页码 551-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mric.2008.07.011
关键词
Gadolinium-based contrast agents; Late adverse reactions; Nephrogenic systemic fibrosis
Gadolinium-based contrast agents were for many years considered safe, but this is no longer the case. The least stable agents may trigger the development of nephrogenic systemic fibrosis (NSF), a generalized fibrotic disorder, in renal failure patients. The use of gadodiamide and gadopentetate dimeglumine is now contraindicated in Europe and Japan in patients who have a glomerular filtration rate less than 30 mL/min/1.73 m(2), including those on dialysis. The fear of NSF, however, should not lead to an enhanced MR imaging examination being denied when there is a good clinical indication to give a gadolinium-based contrast agent.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据